Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why Do A&D Customers Care About Sustainability? with Ben Kraft of Clarus

On today’s episode of Glass is in Session, we brought Ben Kraft, also known as the ‘Glass Man Extraordinaire,’ into the studio. Kraft, an A&D sales representative for Clarus, gives his sales and manufacturing insight on the reasons for and the impacts of green design on company-client relationships. Kraft helps answer these questions as…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

On today’s episode of Glass is in Session, we brought Ben Kraft, also known as the ‘Glass Man Extraordinaire,’ into the studio. Kraft, an A&D sales representative for Clarus, gives his sales and manufacturing insight on the reasons for and the impacts of green design on company-client relationships.

Kraft helps answer these questions as we unpack the customers in Clarus’ three key industries (healthcare, higher education, and corporate America), and what is pushing them to buy green. Is it because the common culture is really becoming more interested in saving the environment, or is it from motivation to take advantage of green initiatives like LEED, BREEAM, and the Living Building Challenge? Are certifications like declare labels or environmental product declarations just a simple requirement for these customers, or do they just prefer to choose from sustainable products?

Kraft thinks the two biggest motivators are wellness and price points. Health, wellness and safety are major factors, especially within fields like healthcare and education, considering the people in those buildings are near these materials every day for extensive periods of time. Same things goes for the back end; B2B clients want to know that the products they’re purchasing promote the wellness and safety of the designers and manufacturers creating them. But it’s difficult to deny price point is a big motivator. Budgets are always tight, and finding a lower cost solution is always appealing. What Kraft points out, though, is that a high quality sustainable product won’t come cheap, and customers aren’t being dissuaded by the price.

How do we convince the client-side of the AEC industry to keep using sustainable products, how does educating the end user encourage more B2B sales, and where do Clarus’ Glassboards fit into all of this? We discuss the certifications that these products have, what they mean to the companies that employ them, and what this means for our future on this episode of Glass is in Session.

For more episodes of Glass is in Session, head to Clarus’ site.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512